SC: Blacklisting Quashed for Denying Tender Retesting Right

• The Supreme Court quashed the blacklisting and debarment of JPEE Drugs by Madhya Pradesh authorities.
• The Court ruled that denying JPEE Drugs the right to retest drug samples, as per tender procedures, violated its ability to challenge adverse reports.
• Authorities failed to follow mandatory tender procedures for second-sample testing, and delays led to the drug samples expiring.
• The Supreme Court emphasized that blacklisting, carrying serious civil consequences, requires strict adherence to tender document procedures.
• Punitive actions based solely on initial adverse reports are unsustainable if retesting opportunities are denied or delayed until sample expiry.

The Supreme Court underscored that administrative or contractual actions, such as blacklisting, which carry significant civil consequences, must strictly conform to the procedures stipulated within the tender document.

Authorities in Madhya Pradesh initiated blacklisting and debarment proceedings against M/s JPEE Drugs following allegations of substandard drug supplies. The case originated from a tender issued by the Department of Public Health and Family Welfare, through M.P. Public Health Services Corporation Limited, Bhopal, for the procurement of medicines for various government hospitals across the state. JPEE Drugs, a licensed manufacturer and supplier, had secured a contract to provide Ascorbic Acid (Vitamin C) Tablets IP 500 mg and Ethambutol Hydrochloride Tablets IP 400 mg.

After the firm supplied these medicines, a show-cause notice was issued on September 23, 2024, alleging that the supplied drugs failed quality tests. The notice included reports indicating that four batches of Ethambutol Hydrochloride Tablets IP 400 mg and three batches of Ascorbic Acid (Vitamin C) Tablets IP 500 mg were "Not of Standard Quality" (NSQ). Consequently, the authorities debarred JPEE Drugs for two years from supplying Ethambutol Hydrochloride Tablets IP 400 mg and demanded a deposit of Rs 3,47,375 for the batch value. Separately, the firm faced a three-year blacklisting, prohibiting its participation in future tenders by MPPHSCL, along with a demand for Rs 6,77,219 for the aggregate batch value of the NSQ Ascorbic Acid tablets. Despite the firm's reply and representation, the blacklisting and debarment decisions, originally passed on September 30, 2024, were reiterated on October 1, 2024. The firm's subsequent challenge, including a writ petition and review petition, was dismissed by the Madhya Pradesh High Court.

The Supreme Court ultimately intervened, overturning the blacklisting and debarment orders against JPEE Drugs. The apex court determined that the authorities had failed to adhere to the mandatory procedure outlined in the tender document concerning second-sample testing. A crucial aspect of the ruling highlighted that any entity facing penalties based on a drug sample laboratory test possesses a fundamental right to contest the report through retesting by a superior laboratory.

The Court observed that the subsequent delay in the process led to the expiration of the drug batches, thereby depriving JPEE Drugs of the opportunity to independently verify the adverse test reports. This procedural lapse, combined with the lost chance for re-testing, rendered the blacklisting and debarment orders legally unsustainable. The Supreme Court also noted that the High Court had erred by directing fresh testing of samples at a Central Government Laboratory while simultaneously declining to quash the blacklisting orders, even though the medicines had not expired at that point.

The Supreme Court underscored that administrative or contractual actions, such as blacklisting, which carry significant civil consequences, must strictly conform to the procedures stipulated within the tender document. This ruling reinforces the principle of Supreme Court tender procedure compliance and Administrative action procedural fairness in government contracts. The Court emphasized that when the State either fails to provide an opportunity for retesting or causes delays that result in the expiry of a drug's shelf life, punitive measures based solely on an initial adverse report cannot be upheld.

This judgment provides critical clarity on the right to retest drug samples and its importance in ensuring equitable treatment for firms involved in public procurement. The quashing of the JPEE Drugs blacklisting serves as a precedent, affirming that the SC blacklisting tender retesting right is a valuable safeguard against arbitrary administrative actions. It mandates that authorities must meticulously follow prescribed protocols, particularly when actions like blacklisting can severely impact a firm's business and reputation, underscoring the Blacklisting civil consequences India faces when procedural fairness is not observed.

Lawyers should advise clients facing blacklisting or debarment to meticulously review the tender document for procedural rights, such as retesting, as non-compliance by authorities can be grounds for challenging such actions. Compliance officers in procuring entities must ensure strict adherence to stipulated blacklisting procedures to avoid legal reversals.

Source: Original reporting on a Supreme Court judgment